Investigators identified candidate protein markers from aptamer-based proteomic profiles of samples from women with or without late-onset preeclampsia.
A genome-wide association study of children whose mothers had preeclampsia, conducted as part of the InterPregGen study, implicates variants near the FLT1 gene in the condition.
Using absolute and relative gene expression analyses, researchers identified expression patterns associated with preeclampsia in dozens of placental tissue samples.
Roche's molecular diagnostics business, which makes up 17 percent of its overall diagnostics sales, grew 11 percent, driven by virology testing and sequencing.
The prospective study found the markers were able to rule out a woman's chance of developing preeclampsia with a negative predictive value of 99.3 percent.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
